FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis September 13, 2018 11:35 AM Eastern Daylight Time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results